• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi, Evotec collaborate to reinforce biomedical research in Toulouse

Sanofi, Evotec collaborate to reinforce biomedical research in Toulouse

March 25, 2015
CenterWatch Staff

Sanofi has signed a strategic collaboration agreement with Evotec, a drug discovery alliance and development partnership company, for scientific activities at the Sanofi R&D site in Toulouse (Haute-Garonne), France. This strategic collaboration aims to sustain a high level of scientific and technological activities, maintain jobs and attract new talent and projects to the site.

The collaboration agreement includes the divestiture to Evotec of Sanofi's Research and Technological platform activities, which match Evotec's areas of experience as well as the continuation of these activities and the corresponding transfer of the employees currently involved in these activities.

For Sanofi, the strategic collaboration also involves a financial commitment of $274 million over a five-year period for the implementation of a multi-year research program including, among other projects, the creation of a support fund dedicated to developing scientific collaboration with academic partners in France.

This agreement successfully concludes the exclusive discussions entered into by the two companies on Dec. 2, 2014. It also follows the information-consultation procedure of employee representative institutions, finalized by Sanofi on March 10. This procedure has been supplemented with an agreement on supporting measures signed by three trade unions, CFE-CGC, CFTC and CFDT, resulting from a constructive social dialogue. The agreement is expected to be effective as of March 31.

Evotec has thus become the sixth Bioparc resident company to benefit from the services and scientific infrastructures which Sanofi’s support platform offers to all start-ups, biotechnology companies and academic players seeking to settle in the heart of the Oncopole.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing